Progress in research and development related to CT-01 project

Current Report No. 3/2022

Date of preparation: 11 January 2022

Subject: Progress in research and development related to CT-01 project 

Legal basis: Art. 17(1) of MAR – inside information

The Management Board of Captor Therapeutics S.A., with its registered office in Wrocław ("Company") hereby announces significant scientific progress in the CT-01 project which is focused on the development of targeted protein degradation therapy for hepatocellular carcinoma.

The Company obtained preclinical proof-of-concept data that confirm the potent antitumor activity of two CT-01 lead compounds in a liver cancer mouse xenograft model. These new results demonstrate that oral administration of these CT-01 candidates results in tumour regression in a Hep 3B2.1-7 mouse model of hepatocellular carcinoma.

This preclinical data represents a significant milestone and supports the further advancement of the Captor’s candidates towards IND-enabling studies. Simultaneously, these results demonstrate the capability of the Company to rationally discover and optimise molecular glue-type degraders using its Optigrade^TM platform.

The Company will inform about further progress in CT-01 project in accordance with legal requirements.